New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
10:00 EDTEMC, SGEN, REGN, NGS, BERY, SOHU, VMW, SDRL, RBC, HITT, INVN, XOMA, SDLP, PDLI, FCSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Berry Plastics (BERY) initiated with a Buy at Citigroup... Fairchild Semiconductor (FCS) initiated with a Positive at Susquehanna... Hittite Microwave (HITT) initiated with an Outperform at Wells Fargo... New Gold (NGD) initiated with an Outperform at Credit Suisse... PDL BioPharma (PDLI) initiated with a Neutral at Credit Suisse... Regal-Beloit (RBC) initiated with a Buy at Janney Capital... Regeneron (REGN) initiated with an Outperform at Credit Suisse... Seadrill Partners (SDLP) initiated with a Buy at Citigroup... Seadrill (SDRL) initiated with a Buy at Deutsche Bank... Seattle Genetics (SGEN) initiated with an Outperform at Credit Suisse... XOMA (XOMA) initiated with an Outperform at Credit Suisse... VMWare (VMW) initiated with a Hold at Craig-Hallum... EMC (EMC) initiated with a Hold at Craig-Hallum... InvenSense (INVN) initiated with a Buy at Maxim... Sohu.com (SOHU) initiated with an Inderweight at HSBC.
News For BERY;FCS;HITT;NGS;PDLI;RBC;REGN;SDLP;SDRL;SGEN;XOMA;VMW;EMC;INVN;SOHU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 23, 2015
09:59 EDTINVNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:02 EDTRBCRegal-Beloit reinstated with a Neutral at Goldman
Target $83.
07:56 EDTINVNInvenSense initiated with an Outperform at Barrington
Subscribe for More Information
February 20, 2015
16:48 EDTREGNDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
12:07 EDTREGNEYLEA reimbursment could be influenced by UK recommendation, says Piper Jaffray
Subscribe for More Information
12:01 EDTREGNNICE recommends EYLEA for DME, but only in certain cases
Subscribe for More Information
07:08 EDTREGNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
16:28 EDTREGNOn The Fly: Closing Wrap
Subscribe for More Information
15:58 EDTREGNRegeneron downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
10:32 EDTBERYHigh option volume stocks:
Subscribe for More Information
10:00 EDTREGNRegeneron Praluent launch costs a concern, says Piper Jaffray
Subscribe for More Information
09:01 EDTREGNData to accelerate growth of Regeneron's Eylea, says Bernstein
Subscribe for More Information
08:48 EDTVMWVMware to hold a conference call with Jefferies
Jefferies Analyst John DiFucci co-hosts a conference call to discuss the VMware vSphere 6 and VMware Integrated OpenStack (VIO) on February 19 at 12 pm. Webcast Link
07:28 EDTREGNRegeneron data better than expected, says RBC Capital
RBC Capital believes that Protocol-T results for Regneron's (REGN) Eylea were better than expected. The firm says that Eylea improved the vision of all patients more than Roche's treatments,and was much better than Roche's drugs in treating patients with moderate or worse vision loss. The firm keeps a $490 price target and Outperform rating on Regeneron.
06:56 EDTREGNData support Regeneron drug over competition, says Deutsche Bank
Subscribe for More Information
06:45 EDTREGNStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
February 18, 2015
17:23 EDTREGNRegeneron reports positive results for Eylea injection in diabetic macular edema
Subscribe for More Information
09:05 EDTSGENSeattle Genetics submits supplemental BLA to FDA for Phase 3 Aethera trial
Seattle Genetics announced that it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration based on data from the phase 3 AETHERA trial of ADCETRIS as consolidation therapy immediately following an autologous stem cell transplant in Hodgkin lymphoma patients at high risk of relapse. ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma. ADCETRIS is approved in relapsed HL and sALCL but is currently not approved for consolidation therapy in HL patients immediately after ASCT. The supplemental BLA is based on positive results from a phase 3 clinical trial called AETHERA that were presented at the 56th American Society of Hematology Annual Meeting in December 2014. Results from the AETHERA trial in 329 HL patients at high risk of relapse included: The trial achieved its primary endpoint and demonstrated a significant increase in progression-free survival per independent review facility, with a hazard ratio of 0.57 and a p-value of 0.001. Median PFS was 43 months for patients who received ADCETRIS versus 24 months for patients who received placebo. The two-year PFS rate was 63 percent in the ADCETRIS arm compared to 51 percent in the placebo arm. The PFS benefit was consistent across all pre-specified subgroups, including primary refractory patients, patients who relapsed within twelve months of frontline therapy and patients who relapsed after twelve months with extranodal disease.
07:38 EDTVMWVMware named a Franchise Pick at Jefferies
Subscribe for More Information
03:20 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use